Skip to Content
Søg Menu

SABCS2020: Trastuzumab Deruxtecan Continues to Demonstrate Durable Responses in HER2 Positive Metastatic Breast Cancer

In this MEDtalk Fabrice André, Professor, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France presents the key clinical messages from DESTINY-Breast01 study

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Related

Hatem Azim

Using Fertility Options May be Safe for Patients with HR-positive Breast Cancer

/ Hatem Azim
SABCS23Brystcancer Play the Video 10:10
Terry Mamounas

The Effectiveness of Regional Nodal Radiation in Patients with Breastcancer

/ Eleftherios (Terry) P. Mamounas
SABCS23Brystcancer Play the Video 13:26

SABCS 2023: HR-Positive Breast Cancer Patients May Safely Use Fertility Options

/ BestPractice Nordic
SABCS23Brystcancer

SABCS 2023: Younger Postmenopausal Women May Safely Skip Adjuvant Radiotherapy

/ BestPractice Nordic
SABCS23Brystcancer

SABCS 2023: Neoadjuvant Chemotherapy May Reduce Regional Nodal Irradiation in Breast Cancer Patients

/ BestPractice Nordic
SABCS23Brystcancer

SABCS 2023: Blood Hormone Levels – a Key to Effective Breast Cancer Prevention in Post-Menopausal Women

/ BestPractice Nordic
SABCS23Brystcancer

BestPractice Nordic is covering SABCS 2023

/ BestPractice Nordic
SABCS23Brystcancer
Hope Rugo

The Potential of Trodelvy® for Patients with HR+/HER2- Metastatic Breast Cancer Patients Treated with Trodelvy®

/ Hope S. Rugo
Brystcancer Play the Video 6:03
Elsebeth Lynge

Does breast density affect the risk of breast cancer?

/ Elsebeth Lynge
SABCS22Brystcancer Play the Video 6:29
Back to top